Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

• Autori principali: Zalmai Hakimi (Autore), Con Kelleher (Autore), Samuel Aballéa (Autore), Khaled Maman (Autore), Jameel Nazir (Autore), Colette Mankowski (Autore), Isaac Odeyemi (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator an...